257 related articles for article (PubMed ID: 26459175)
21. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
23. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
24. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
[TBL] [Abstract][Full Text] [Related]
26. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
[TBL] [Abstract][Full Text] [Related]
27. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A; Gallego J; Guillén Ponce C; Vera R; Iranzo V; Ales I; Arévalo S; Pisa A; Martín M; Salud A; Falcó E; Sáenz A; Manzano Mozo JL; Pulido G; Martínez Galán J; Pazo-Cid R; Rivera F; García García T; Serra O; Fernández Parra EM; Hurtado A; Gómez Reina MJ; López Gomez LJ; Martínez Ortega E; Benavides M; Aranda E;
Eur J Cancer; 2017 Apr; 75():73-82. PubMed ID: 28222309
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
30. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Reni M; Cereda S; Galli L
Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
[TBL] [Abstract][Full Text] [Related]
31. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
34. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Hu ZI; Bendell JC; Bullock A; LoConte NK; Hatoum H; Ritch P; Hool H; Leach JW; Sanchez J; Sohal DPS; Strickler J; Patel R; Wang-Gillam A; Firdaus I; Yu KH; Kapoun AM; Holmgren E; Zhou L; Dupont J; Picozzi V; Sahai V; O'Reilly EM
Cancer Med; 2019 Sep; 8(11):5148-5157. PubMed ID: 31347292
[TBL] [Abstract][Full Text] [Related]
36. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
38. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
[TBL] [Abstract][Full Text] [Related]
39. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
